Ryutaro Shimazaki
InvestorPartner at Catalys Pacific
About
Ryutaro is a Partner at Catalys Pacific. He previously served as Executive Officer and Global Head of Nephrology R&D at Kyowa Kirin, where he led the development and regulatory filings of medicines including Darbepoetin alfa, Evocalcet, Pegfilgrastim, and Burosumab, and oversaw more than 10 product launches across Japan and East Asia. He is a graduate of Tokyo University of Science and a qualified pharmacist.
Contact· self-published, not guessed
Invests in
Biotech
Colleagues at Catalys Pacific
Ariel Miura
Analyst at Catalys Pacific
Ashwin Ram
Partner at Catalys Pacific
Brian Taylor Slingsby
Founder & Managing Director, MD, PhD, MPH at Catalys Pacific
BT Slingsby
Founder and Managing Director at Catalys Pacific
Hayato Urabe
Vice President at Catalys Pacific
Hidemasa Tanigaki
Operating Partner at Catalys Pacific
Hiromi Miwa
Principal at Catalys Pacific
Jay Shepard
Venture Partner at Catalys Pacific
Frequently asked questions
- Who is Ryutaro Shimazaki?
- Ryutaro is a Partner at Catalys Pacific. He previously served as Executive Officer and Global Head of Nephrology R&D at Kyowa Kirin, where he led the development and regulatory filings of medicines including Darbepoetin alfa, Evocalcet, Pegfilgrastim, and Burosumab, and oversaw more than 10 product launches across Japan and East Asia. He is a graduate of Tokyo University of Science and a qualified pharmacist.
- Where does Ryutaro Shimazaki work?
- Ryutaro Shimazaki is Partner at Catalys Pacific.
- What does Ryutaro Shimazaki invest in?
- Ryutaro Shimazaki invests in Biotech.